Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Inovio Pharma (INO) plans to advance INO-3112 vaccine in combination with MedImmune’s immuno-oncology molecules into a Phase 1 study of HPV-related cancers in 2016

Source Link:: http://seekingalpha.com/article/3958306-inovio-pharmaceuticals-ino-ceo-joseph-kim-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

INO

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "Thought leaders have suggested that such combinations represent an important avenue to take patients’ response-rate beyond the 20% to 40%, typically achieved by checkpoint inhibitors used as monotherapy. We are talking about powerful one to punch"
-CEO Joseph Kim

http://seekingalpha....

Additional Relevant Details Completed enrollment of 22 subjects in the phase I study of our HPV-driven cancer immunotherapy, INO-3112, in head & neck cancer patients. We expect to report additional immune response and safety data in 4Q 2016.

http://ir.inovio.com...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Aug 28, 2016

Occurred Source:

http://ir.inovio.com/news/news-releases/news-releases-details/2016/Inovio-Pharmaceuticals-Reports-2016-Second-Quarter-Financial-Results/default.aspx

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Ino-3112, Phase 1 Trial, Hpv Infections, Cancer immunotherapy